Compositions for and Methods of Detecting, Diagnosing, and Prognosing Thymic Cancer
AssigneesIndiana University Research and Technology Corporation, Castle Biosciences, Inc.
InventorsSunil Badve, Yesim Gokmen-Polar, Patrick J. Loehrer, Robert Cook, Derek Maetzold
Life of this patent
Estimating the term…
Abstract
Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.
Claims14
A kit for detecting thymic cancer, the kit comprising a plurality of probes or a plurality of oligonucleotide primer pairs, wherein a) each probe specifically binds to one distinct biomarker, fragment or variant thereof or b) each oligonucleotide primer pair specifically amplifies a distinct biomarker, fragment or variant thereof, wherein the biomarker, fragment or variant thereof is selected from the group of biomarkers consisting of JPH1, ALDH1A3, SPOCK1, NGB, STC1, STC 2, AKR1B10, ENPEP, GOLSYN, RPL39, LAMP2, ABHD7, RBPMS2, C9orf93, SESN3, MRRF, NEBL, PRRX1, C14orf39, LEPR, DTNA, LCA5, RSPO3, IGF2BP2, GPR98, TIAM2, SLC9A2, MAB21L2, SCUBE2, DACT3, COL11A1 and SLC7A11;
- or
- wherein a) each probe specifically binds to one distinct biomarker, fragment or variant thereof or b) each oligonucleotide primer pair specifically amplifies a distinct biomarker, fragment or variant thereof, wherein the biomarker, fragment or variant thereof is selected from the group of biomarkers consisting of COL11A1, DACT3, SLC9A2, PRRX1, PDGFRL, SCUBE2, MAB21L2, FCGBP, MAOA, CTGF, MET, NEBL, GPR98, GLDN, IGSF11, PCDH19, C6 orf118, GOLSYN, BCMO1, PTN, LAMP2, LRRC17, DDX60, GEM, FRMD6, KGFLP1, C9orf93, NGB, AKR1B10, JPH1 STC1, STC2 and SLC7A11;
- or
- wherein a) each probe specifically binds to one distinct biomarker, fragment or variant thereof or b) each oligonucleotide primer pair specifically amplifies a distinct biomarker, fragment or variant thereof, wherein the biomarker, fragment or variant thereof is selected from the group of biomarkers consisting of DACT3, JPH1, AKR1B10, COL11A1, SLC9A2, PDGFRL, FCGBP, PRRX1, SERPINF1, NGB, SCUBE2, MAB21L2, LEPR, LCA5, GPR98, RSPO3, STC1, STC2 and SLC7A11.
-9. (canceled)
A method of detecting thymic cancer in a subject having or suspected of having thymic cancer, the method comprising the steps of:
- a) determining expression levels of nucleic acid transcripts or expression products thereof of a plurality of biomarkers in a sample from the individual,
- b) determining the level of expression of said transcripts or expression products thereof in a control sample;
- and
- c) comparing the level of expression of said transcripts or expression products thereof in the subject sample relative to the level of expression of said transcripts or expression products thereof in the control sample,
- wherein the biomarkers are selected from the group of biomarkers consisting of:
- (i) JPH1, ALDH1A3, SPOCK1, NGB, STC1, STC 2, AKR1B10, ENPEP, GOLSYN, RPL39, LAMP2, ABHD7, RBPMS2, C9orf93, SESN3, MRRF, NEBL, PRRX1, C14orf39, LEPR, DTNA, LCA5, RSPO3, IGF2BP2, GPR98, TIAM2, SLC9A2, MAB21L2, SCUBE2, DACT3, COL11A1 and SLC7A11;
- or
- (ii) COL11A1, DACT3, SLC9A2, PRRX1, PDGFRL, SCUBE2, MAB21L2, FCGBP, MAOA, CTGF, MET, NEBL, GPR98, GLDN, IGSF11, PCDH19, C6 orf118, GOLSYN, BCMO1, PTN, LAMP2, LRRC17, DDX60, GEM, FRMD6, KGFLP1, C9orf93, NGB, AKR1B10, JPH1 STC1, STC2 and SLC7A11;
- or
- (iii) DACT3, JPH1, AKR1B10, COL11A1, SLC9A2, PDGFRL, FCGBP, PRRX1, SERPINF1, NGB, SCUBE2, MAB21L2, LEPR, LCA5, GPR98, RSPO3, STC1, STC2 and SLC7A11;
- and
- wherein a significant modulation in the level of expression of said transcripts or expression products thereof in the subject sample relative to the level of expression of said transcripts or expression products thereof in the control sample is an indication that the subject is afflicted with thymic cancer.
A method of diagnosing early stage thymic cancer in an individual having or suspected of having thymic cancer, the method comprising the steps of:
- determining expression levels of nucleic acid transcripts or expression products thereof of a plurality of biomarkers in a sample from the individual, wherein the biomarkers are selected from the group of biomarkers consisting of JPH1, ALDH1A3, SPOCK1, NGB, STC1, STC 2, AKR1B10, ENPEP, GOLSYN, RPL39, LAMP2, ABHD7, RBPMS2, C9orf93, SESN3, MRRF, NEBL, PRRX1, C14orf39, LEPR, DTNA, LCA5, RSPO3, IGF2BP2, GPR98, TIAM2, SLC9A2, MAB21L2, SCUBE2, DACT3, COL11A1 and SLC7A11;
- and
- comparing expression levels of the plurality of biomarkers to expression levels of at least one control or reference,
- wherein a significant modulation in the level of expression of said transcripts or expression products thereof in the subject sample relative to the level of expression of said transcripts or expression products thereof in the control sample is an indication that the subject is afflicted with early stage thymic cancer.
-28. (canceled)
Dependencies are inferred from the claim text.